{
    "clinical_study": {
        "@rank": "132925", 
        "arm_group": [
            {
                "arm_group_label": "Bevacizumab", 
                "arm_group_type": "Experimental", 
                "description": "Bevacizumab200mg by intrapleural administration"
            }, 
            {
                "arm_group_label": "Pulvis talci", 
                "arm_group_type": "Active Comparator", 
                "description": "Pulvis talci 4g by intrapleural administration"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with Malignant pleural effusion can be diagnosis advanced cancer. Currently\n      recognized as the most reliable method to control malignant pleural effusion is pleural\n      fixed or thoracic catheter drainage. The most effective pleural fixed agent is pulvis talci,\n      but there are about 30% relapse rate. Thoracic drainage can lead to some complications, such\n      as chest infections, catheter migration and blockage etc. The investigators need a reliable\n      methods to solve dyspnea and other symptoms caused by malignant pleural effusion, and\n      improve quality of life. The purpose of this study was to determine the efficacy and Safety\n      of intrapleural Bevacizumab versus pulvis talci as treatment for malignant pleural effusions\n      (MPE) in patients."
        }, 
        "brief_title": "Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion", 
        "condition": "Malignant Pleural Effusion", 
        "condition_browse": {
            "mesh_term": [
                "Pleural Effusion", 
                "Pleural Effusion, Malignant"
            ]
        }, 
        "detailed_description": {
            "textblock": "Background\uff1a Patients with Malignant pleural effusion can be diagnosis advanced cancer.\n      Currently recognized as the most reliable method to control malignant pleural effusion is\n      pleural fixed or thoracic catheter drainage. The most effective pleural fixed agent is\n      pulvis talci, but there are about 30% relapse rate. Thoracic drainage can lead to some\n      complications, such as chest infections, catheter migration and blockage etc. The\n      investigators need a reliable methods to solve dyspnea and other symptoms caused by\n      malignant pleural effusion, and improve quality of life. The purpose of this study was to\n      determine the efficacy and Safety of intrapleural Bevacizumab versus pulvis talci as\n      treatment for malignant pleural effusions (MPE) in patients.\n\n      Methods:\n\n      A unblended, randomized study to compare the inhibition of two treatment methods in\n      malignant pleural effusion. Consecutive 183 patients were randomly assigned to two groups, A\n      group is Bevacizumab200mg by intrapleural administration; B group is injected pulvis talci\n      with closed thoracic drainage."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnose malignant pleural effusions by:\n\n               -  Diagnose malignant pleural neoplasms by histopathology\n\n               -  Recurrent pleural effusion, Histologically or cytologically confirmed diagnosis\n                  of cancer\n\n          2. Written informed consent\n\n        Exclusion Criteria:\n\n          1. <18years of age\n\n          2. Expected survival <3 months\n\n          3. Chest infection, chylothorax, pleurodesis or ipsilateral lung surgery once\n\n          4. Planned chemotherapy\n\n          5. Pregnancy or breast-feeding (women of child-bearing potential)\n\n          6. Not signed informed consent or non-compliance with treatment protocols"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "183", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054078", 
            "org_study_id": "CTSL002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bevacizumab", 
                "description": "Bevacizumab200mg by intrapleural administration", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "Pulvis talci", 
                "description": "Pulvis talci 4g by intrapleural administration", 
                "intervention_name": "Pulvis talci", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "contact": {
                "email": "luqiang@fmmu.edu.cn", 
                "last_name": "qiang lu, doctor", 
                "phone": "18092920605"
            }, 
            "facility": {
                "address": {
                    "city": "Xi'an", 
                    "country": "China", 
                    "state": "Shaanxi"
                }, 
                "name": "Tangdu Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Intrapleural Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion, A Randomized, Multicenter Study", 
        "overall_contact": {
            "email": "lxfchest@fmmu.edu.cn", 
            "last_name": "xiaofei li, doctor", 
            "phone": "13909111010"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Observed chest drainage every day", 
            "measure": "Changes in chest drainage", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054078"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tang-Du Hospital", 
            "investigator_full_name": "Xiaofei Li", 
            "investigator_title": "chief physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "VAS: Visual Analogue Scale", 
                "measure": "the average daily VAS defining breathlessness", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year"
            }, 
            {
                "description": "VAS: Visual Analogue Scale", 
                "measure": "Average daily thoracalgia assessed using VAS score", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "percentage of adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "Length of Stay", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year"
            }
        ], 
        "source": "Tang-Du Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tang-Du Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}